AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Grants from the National Institutes of Health come with additional money for overhead. Proposed funding cuts would leave ...

The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

IRVINE, Calif. - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a biotechnology company with a market capitalization of $284.54 million and a remarkable 170% stock return over the past year according to ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...